• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by AlloVir Inc.

    10/11/24 4:02:13 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVR alert in real time by email
    SC 13G 1 alvr1011240sc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    AlloVir, Inc.
    (Name of Issuer)
     
    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

      019818103  
      (CUSIP Number)  
     
    September 30, 2024
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)
         
      o Rule 13d-1(c)
         
      o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 
     

     

    CUSIP No.  019818103
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Capital Advisors LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    11,202,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    11,202,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,202,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, PN

     

     Page 2 of 8 
     

     

    CUSIP No.  019818103
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Investments Master Fund LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    11,202,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    11,202,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,202,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO, PN

     

     Page 3 of 8 
     

     

    CUSIP No.  019818103
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ting Jia

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    China

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    11,202,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    11,202,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,202,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, IN

     

     Page 4 of 8 
     

     

    Item 1(a). Name of Issuer:
       
       AlloVir, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
       1100 Winter Street, Waltham, MA 02451
       
    Item 2(a). Name of Person Filing:
       
      

    This statement is being jointly filed by:

     

    Octagon Capital Advisors LP ("Octagon")

    Octagon Investments Master Fund LP ("Master Fund")

    Ting Jia, as the principal beneficial owner of Octagon ("Mr. Jia")

     

    Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

     

    Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer's Common Shares directly owned by the Master Fund.

     

       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
       The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065
       
    Item 2(c). Citizenship:
       
       Octagon is a Delaware limited partnership.  The Master Fund is an exempted limited partnership established in the Cayman Islands.  Mr. Jia is a Chinese citizen.
       
    Item 2(d). Title of Class of Securities:
       
       Common Stock, $0.0001 par value (the “Common Shares”)
       
    Item 2(e). CUSIP Number:  019818103

     

     Page 5 of 8 
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) o Broker or dealer registered under Section 15 of the Act;
      (b) o Bank as defined in Section 3(a)(6) of the Act;
      (c) o Insurance company as defined in Section 3(a)(19) of the Act;
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) o A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a) Amount Beneficially Owned: 11,202,000
       (b) Percent of Class: 9.7%
               The percentage reported on this Schedule 13G is calculated based upon 115,365,282 Common Shares outstanding as of August 2, 2024, as reported in the Form 10-Q filed by the Issuer on August 9, 2024.  
       (c) Number of shares as to which such person has:
          (i) sole power to vote or to direct the vote: 0
          (ii) shared power to vote or to direct the vote: 11,202,000
          (iii) sole power to dispose or to direct the disposition of: 0
          (iv) shared power to dispose or to direct the disposition of: 11,202,000

     

     Page 6 of 8 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Octagon is the investment advisor to the Master Fund and other accounts.  Mr. Jia is the control person of Octagon.  The Master Fund holds the Common Shares for the benefit of its investors.  The Master Fund and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     Page 7 of 8 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 11, 2024 OCTAGON CAPITAL ADVISORS LP
       
      /s/ Ting Jia
      Name: Ting Jia
      Title: Managing Member

     

     

     

      OCTAGON INVESTMENTS MASTER FUND LP
      By: Octagon Investments GP, LLC, its general partner
       
      /s/ Ting Jia
      Name: Ting Jia
      Title: Managing Member
     

     

     

     

    TING JIA

     

    /s/ Ting Jia

      Name: Ting Jia

     

     

    Pages 8 of 8

     

     

     

    Get the next $ALVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVR

    DatePrice TargetRatingAnalyst
    12/26/2023$17.00 → $1.00Buy → Underperform
    BofA Securities
    12/22/2023Outperform → Market Perform
    Leerink Partners
    12/22/2023Overweight → Underweight
    JP Morgan
    12/22/2023Overweight → Neutral
    Piper Sandler
    8/18/2023$17.00Buy
    BofA Securities
    2/10/2022$32.00 → $30.00Outperform
    SVB Leerink
    1/18/2022$48.00 → $45.00Overweight
    Morgan Stanley
    12/17/2021$37.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $ALVR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by AlloVir Inc.

      SCHEDULE 13D - Kalaris Therapeutics, Inc. (0001754068) (Subject)

      3/25/25 7:40:09 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AlloVir Inc.

      SCHEDULE 13G/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)

      3/20/25 4:32:25 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Leadership Update, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Regulation FD Disclosure

      8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)

      3/18/25 5:04:06 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AlloVir downgraded by BofA Securities with a new price target

      BofA Securities downgraded AlloVir from Buy to Underperform and set a new price target of $1.00 from $17.00 previously

      12/26/23 7:17:53 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir downgraded by Leerink Partners

      Leerink Partners downgraded AlloVir from Outperform to Market Perform

      12/22/23 10:47:30 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir downgraded by JP Morgan

      JP Morgan downgraded AlloVir from Overweight to Underweight

      12/22/23 9:11:15 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AlloVir Inc.

      SC 13G - Allovir, Inc. (0001754068) (Subject)

      10/11/24 4:02:13 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AlloVir Inc.

      SC 13G/A - Allovir, Inc. (0001754068) (Subject)

      8/2/24 6:25:25 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by AlloVir Inc. (Amendment)

      SC 13G/A - Allovir, Inc. (0001754068) (Subject)

      2/13/24 4:54:00 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      3/4/24 5:37:52 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      2/28/24 1:06:25 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

      Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (NASDAQ:ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-s

      12/22/23 7:00:00 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Leadership Updates

    Live Leadership Updates

    See more
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      3/4/24 5:37:52 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      2/28/24 1:06:25 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

      - Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology

      5/16/23 7:00:00 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Hagen Brett R sold $8,135 worth of shares (907 units at $8.97), decreasing direct ownership by 32% to 1,925 units (SEC Form 4)

      4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/27/25 7:19:58 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Akkaraju Srinivas claimed ownership of 3,578 shares (SEC Form 3)

      3/A - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/26/25 5:06:57 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Samsara Biocapital Gp, Llc claimed ownership of 11,448,081 shares (SEC Form 3)

      3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/25/25 7:38:53 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care